Letermovir for preventing cytomegalovirus disease after a stem cell transplant

  • Technology appraisal guidance
  • TA591
  • Published: 

Resource impact statement

Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,000 per 100,000 population).

This is because the population size is small. It is estimated that around 600 people per year are eligible for treatment with letermovir for preventing cytomegalovirus disease after a stem cell transplant.

The company has a commercial arrangement (simple discount patient access scheme). This makes letermovir available to the NHS with a discount. The size of the discount is commercial in confidence. For enquiries about the patient access scheme please contact LetermovirPAS@merck.com.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: